Mutations at hypothetical binding site 2 in insulin and insulin-like growth factors 1 and 2 result in receptor- and hormone-specific responses

Autor: Anja Muždalo, Katarína Mitrová, Irena Selicharová, Ondřej Socha, Miloš Buděšínský, Pavlo Potalitsyn, Jelena Radosavljević, Michaela Černeková, Milan Fábry, Martina Chrudinová, Lenka Žáková, Jingjing Lin, Martin Lepšík, Kateřina Hanková, Kateřina Macháčková, Květoslava Mlčochová, Jiří Jiráček, Pavel Hobza, Yevgen P. Yurenko
Rok vydání: 2019
Předmět:
0301 basic medicine
insulin
receptor binding
medicine.medical_treatment
Biochemistry
structure-function
Receptor tyrosine kinase
Receptor
IGF Type 1

03 medical and health sciences
Protein Domains
Insulin-Like Growth Factor II
medicine
structural biology
Humans
Abnormalities
Multiple

Amino Acid Sequence
Insulin-Like Growth Factor I
Binding site
Receptor
Nuclear Magnetic Resonance
Biomolecular

Molecular Biology
Growth Disorders
hormone analog
Binding Sites
peptide hormone
030102 biochemistry & molecular biology
biology
Chemistry
Insulin
Mutagenesis
Cell Biology
insulin-like growth factor (IGF)
molecular dynamics
Receptor
Insulin

Insulin receptor
030104 developmental biology
Protein Structure and Folding
Mutation
receptor tyrosine kinase
biology.protein
NMR structure
Hormone analog
complex
mutagenesis
receptor autophosphorylation
Protein Binding
Hormone
Zdroj: The Journal of Biological Chemistry
ISSN: 0021-9258
DOI: 10.1074/jbc.ra119.010072
Popis: Information on how insulin and insulin-like growth factors 1 and 2 (IGF-1 and -2) activate insulin receptors (IR-A and -B) and the IGF-1 receptor (IGF-1R) is crucial for understanding the difference in the biological activities of these peptide hormones. Cryo-EM studies have revealed that insulin uses its binding sites 1 and 2 to interact with IR-A and have identified several critical residues in binding site 2. However, mutagenesis studies suggest that Ile-A10, Ser-A12, Leu-A13, and Glu-A17 also belong to insulin's site 2. Here, to resolve this discrepancy, we mutated these insulin residues and the equivalent residues in IGFs. Our findings revealed that equivalent mutations in the hormones can result in differential biological effects and that these effects can be receptor-specific. We noted that the insulin positions A10 and A17 are important for its binding to IR-A and IR-B and IGF-1R and that A13 is important only for IR-A and IR-B binding. The IGF-1/IGF-2 positions 51/50 and 54/53 did not appear to play critical roles in receptor binding, but mutations at IGF-1 position 58 and IGF-2 position 57 affected the binding. We propose that IGF-1 Glu-58 interacts with IGF-1R Arg-704 and belongs to IGF-1 site 1, a finding supported by the NMR structure of the less active Asp-58-IGF-1 variant. Computational analyses indicated that the aforementioned mutations can affect internal insulin dynamics and inhibit adoption of a receptor-bound conformation, important for binding to receptor site 1. We provide a molecular model and alternative hypotheses for how the mutated insulin residues affect activity.
Databáze: OpenAIRE